![Matthew Klein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Matthew Klein
Directeur Général chez
PTC THERAPEUTICS, INC.
Fortune : 27 M $ au 31/08/2026
Profil
Dr. Matthew B. Klein, MD, is an Independent Director at ClearPoint Neuro, Inc., a President, Chief Executive Officer & Director at PTC Therapeutics, Inc. and a Clinical Associate Professor at Stanford University.
He is on the Board of Directors at ClearPoint Neuro, Inc., PTC Therapeutics, Inc. and PTC Therapeutics International Ltd. Dr. Klein was previously employed as a Chief Medical Officer by BioElectron Technology Corp., a Chief Medical Officer & Senior Vice President by Edison Pharmaceuticals, Inc., and a Chairman-Restorative Burn Surgery by University of Washington.
He received his undergraduate degree from the University of Pennsylvania, a graduate degree from UW School of Public Health and a doctorate degree from Yale University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/08/2026 | 383 868 ( 0,46% ) | 27 M $ | 31/08/2026 | |
| 21/05/2026 | 46 935 ( 0,15% ) | 710 596 $ | 31/08/2026 |
Postes actifs de Matthew Klein
| Sociétés | Poste | Début |
|---|---|---|
| CLEARPOINT NEURO, INC. | Directeur/Membre du Conseil | 16/04/2020 |
| PTC THERAPEUTICS, INC. | Directeur Général | 22/03/2023 |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
PTC Therapeutics International Ltd.
 PTC Therapeutics International Ltd. PTC Therapeutics International Ltd. is an Irish biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases with high unmet medical needs. The company is based in DU. The company addresses the root causes of serious genetic, metabolic, and neurological conditions through approaches such as RNA splicing modulation and targeting oxidative stress and inflammation pathways, particularly in central nervous system disorders. Its therapeutic portfolio and pipeline include treatments for rare diseases such as phenylketonuria (PKU), aromatic l-amino acid decarboxylase (AADC) deficiency, Duchenne muscular dystrophy (DMD), hereditary transthyretin amyloidosis (hATTR), familial partial lipodystrophy (FPL), spinal muscular atrophy (SMA), and Friedreich’s ataxia. PTC collaborates with partners to bring treatments to market and supports patients, caregivers, and healthcare providers through educational programs and personalized assistance. The company conducts clinical trials and investigator-initiated studies, maintains dedicated patient engagement teams, and emphasizes corporate responsibility, compliance, and transparency with investors. | Directeur/Membre du Conseil | - |
Anciens postes connus de Matthew Klein
| Sociétés | Poste | Fin |
|---|---|---|
BioElectron Technology Corp.
 BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic treatments for inherited mitochondrial diseases primarily affecting children | Directeur Général | 01/01/2019 |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Edison Pharmaceuticals, Inc.
 Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat mitochondrial diseases | Directeur Technique/Scientifique/R&D | - |
Formation de Matthew Klein
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
57
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Edison Pharmaceuticals, Inc.
Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat mitochondrial diseases | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clearpoint Neuro, Inc.
 Clearpoint Neuro, Inc. Medical SpecialtiesHealth Technology Develops and markets bio technology and surgical products | Health Technology |
PTC Therapeutics International Ltd.
PTC Therapeutics International Ltd. PTC Therapeutics International Ltd. is an Irish biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases with high unmet medical needs. The company is based in DU. The company addresses the root causes of serious genetic, metabolic, and neurological conditions through approaches such as RNA splicing modulation and targeting oxidative stress and inflammation pathways, particularly in central nervous system disorders. Its therapeutic portfolio and pipeline include treatments for rare diseases such as phenylketonuria (PKU), aromatic l-amino acid decarboxylase (AADC) deficiency, Duchenne muscular dystrophy (DMD), hereditary transthyretin amyloidosis (hATTR), familial partial lipodystrophy (FPL), spinal muscular atrophy (SMA), and Friedreich’s ataxia. PTC collaborates with partners to bring treatments to market and supports patients, caregivers, and healthcare providers through educational programs and personalized assistance. The company conducts clinical trials and investigator-initiated studies, maintains dedicated patient engagement teams, and emphasizes corporate responsibility, compliance, and transparency with investors. | |
BioElectron Technology Corp.
BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic treatments for inherited mitochondrial diseases primarily affecting children | Commercial Services |
UW School of Public Health
 UW School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
